Literature DB >> 12435688

Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues.

Lieven J Stuyver1, Stefania Lostia, Marjorie Adams, Judy S Mathew, Balakrishna S Pai, Jason Grier, Phillip M Tharnish, Yongseok Choi, Youhoon Chong, Hyunah Choo, Chung K Chu, Michael J Otto, Raymond F Schinazi.   

Abstract

The antiviral efficacies and cytotoxicities of 2',3'- and 4'-substituted 2',3'-didehydro-2',3'-dideoxycytidine analogs were evaluated. All compounds were tested (i) against a wild-type human immunodeficiency virus type 1 (HIV-1) isolate (strain xxBRU) and lamivudine-resistant HIV-1 isolates, (ii) for their abilities to inhibit hepatitis B virus (HBV) production in the inducible HepAD38 cell line, and (iii) for their abilities to inhibit bovine viral diarrhea virus (BVDV) production in acutely infected Madin-Darby bovine kidney cells. Some compounds demonstrated potent antiviral activities against the wild-type HIV-1 strain (range of 90% effective concentrations [EC(90)s], 0.14 to 5.2 micro M), but marked increases in EC(90)s were noted when the compounds were tested against the lamivudine-resistant HIV-1 strain (range of EC(90)s, 53 to >100 micro M). The beta-L-enantiomers of both classes of compounds were more potent than the corresponding beta-D-enantiomers. None of the compounds showed antiviral activity in the assay that determined their abilities to inhibit BVDV, while two compounds inhibited HBV production in HepAD38 cells (EC(90), 0.25 micro M). The compounds were essentially noncytotoxic in human peripheral blood mononuclear cells and HepG2 cells. No effect on mitochondrial DNA levels was observed after a 7-day incubation with the nucleoside analogs at 10 micro M. These studies demonstrate that (i) modification of the sugar ring of cytosine nucleoside analogs with a 4'-thia instead of an oxygen results in compounds with the ability to potently inhibit wild-type HIV-1 but with reduced potency against lamivudine-resistant virus and (ii) the antiviral activity of beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine against wild-type HIV-1 (EC(90), 0.08 micro M) and lamivudine-resistant HIV-1 (EC(90) = 0.15 micro M) is markedly reduced by introduction of a 3'-fluorine in the sugar (EC(90)s of compound 2a, 37.5 and 494 micro M, respectively).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435688      PMCID: PMC132758          DOI: 10.1128/AAC.46.12.3854-3860.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity.

Authors:  L Cui; R F Schinazi; G Gosselin; J L Imbach; C K Chu; R F Rando; G R Revankar; J P Sommadossi
Journal:  Biochem Pharmacol       Date:  1996-11-22       Impact factor: 5.858

2.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis.

Authors:  J L Martin; C E Brown; N Matthews-Davis; J E Reardon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

Authors:  A A Johnson; A S Ray; J Hanes; Z Suo; J M Colacino; K S Anderson; K A Johnson
Journal:  J Biol Chem       Date:  2001-08-28       Impact factor: 5.157

4.  High-level expression of hepatitis C virus (HCV) structural proteins by a chimeric HCV/BVDV genome propagated as a BVDV pseudotype.

Authors:  J H Nam; J Bukh; R H Purcell; S U Emerson
Journal:  J Virol Methods       Date:  2001-09       Impact factor: 2.014

5.  DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.

Authors:  Raymond F Schinazi; John Mellors; Holly Bazmi; Sharon Diamond; Sena Garber; Karen Gallagher; Romas Geleziunas; Ron Klabe; Michael Pierce; Marlene Rayner; Jing-Tao Wu; Hangchun Zhang; Jennifer Hammond; Lee Bacheler; Douglas J Manion; Michael J Otto; Lieven Stuyver; George Trainor; Dennis C Liotta; Susan Erickson-Viitanen
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Hep AD38 Assay : A High-Throughput, Cell-Based Screen for the Evaluation of Compounds Against Hepatitis B Virus.

Authors:  R W King; S K Ladner
Journal:  Methods Mol Med       Date:  2000

7.  Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus.

Authors:  V C Lai; W Zhong; A Skelton; P Ingravallo; V Vassilev; R O Donis; Z Hong; J Y Lau
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

Authors:  R McKenzie; M W Fried; R Sallie; H Conjeevaram; A M Di Bisceglie; Y Park; B Savarese; D Kleiner; M Tsokos; C Luciano
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

10.  Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.

Authors:  L Cui; S Yoon; R F Schinazi; J P Sommadossi
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  59 in total

1.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  3'-(1,2,3-Triazol-1-yl)-3'-deoxythymidine analogs as substrates for human and Ureaplasma parvum thymidine kinase for structure-activity investigations.

Authors:  Jay Lin; Vincent Roy; Liya Wang; Li You; Luigi A Agrofoglio; Dominique Deville-Bonne; Tamara R McBrayer; Steven J Coats; Raymond F Schinazi; Staffan Eriksson
Journal:  Bioorg Med Chem       Date:  2010-03-15       Impact factor: 3.641

3.  Chemoenzymatic syntheses and anti-HIV-1 activity of glucose-nucleoside conjugates as prodrugs.

Authors:  Tatiana Rodríguez-Pérez; Susana Fernández; Yogesh S Sanghvi; Mervi Detorio; Raymond F Schinazi; Vicente Gotor; Miguel Ferrero
Journal:  Bioconjug Chem       Date:  2010-11-15       Impact factor: 4.774

4.  Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.

Authors:  Brenda I Hernandez-Santiago; Judy S Mathew; Kim L Rapp; Jason P Grier; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

6.  Facile purification of honokiol and its antiviral and cytotoxic properties.

Authors:  Franck Amblard; David Delinsky; Jack L Arbiser; Raymond F Schinazi
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

7.  Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.

Authors:  Krzysztof Pyrc; Berend Jan Bosch; Ben Berkhout; Maarten F Jebbink; Ronald Dijkman; Peter Rottier; Lia van der Hoek
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol.

Authors:  Franck Amblard; Baskaran Govindarajan; Benjamin Lefkove; Kimberly L Rapp; Mervi Detorio; Jack L Arbiser; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2007-06-10       Impact factor: 2.823

9.  Synthesis and anti-HIV-1 screening of novel N'-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides.

Authors:  Sana Aslam; Matloob Ahmad; Muhammad Zia-Ur-Rehman; Catherine Montero; Mervi Detorio; Masood Parvez; Raymond F Schinazi
Journal:  Arch Pharm Res       Date:  2013-07-10       Impact factor: 4.946

10.  Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors.

Authors:  Horrick Sharma; Tino W Sanchez; Nouri Neamati; Mervi Detorio; Raymond F Schinazi; Xiaolin Cheng; John K Buolamwini
Journal:  Bioorg Med Chem Lett       Date:  2013-09-11       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.